Epiphora and xerophthalmia after 131I therapy: The frequency, time of onset, severity, and duration

1933 Objectives The objective of this study was to characterize the frequency (F), time of onset (TOS), severity (S), and duration (D) of epiphora (E) and xerophthalmia (X) after 131I therapy (tx) in patients (pts) with well-differentiated thyroid cancer (WDTC). Methods A prospective IRB-approved survey was performed at MedStar Wash Hosp Ctr between Sept 2012 - Oct 2013 with the following inclusion criteria:(1)>18 y.o. (2)WDTC, (3)131I tx. Pts with a prior 131I tx were excluded. Multiple demographics were obtained. F, TOS, S, and D for E&X were assessed from the time of 131I tx Day 0 (D0) to post-tx scan with surveys performed on D0 and on the day of the post-tx scan (D5 - D10). McNemar9s test was used to compare pre-tx and post-tx responses. Results EX Gr3-4 in 20%(1) & 30%(3); Gr5-6 in 40%(2) & 30%(3); Gr7-8 in 40%(2) & 30%(3); and Gr9-10 in 0%(0) & 0%(0). Of 5 and 10 pts reporting E&X on D0, respectively the D was 0- 24 hrs in 60%(3) & 40%(4). The same data are presented for E&X as to F, TOS, S, D assessed at the post-tx scan. Based on McNemar’s test, the F of reported E&X after 131I tx vs within 30 days prior to 131I tx were not statistically significantly increased. Conclusions Epiphora and xerophthalmia may occur on the day of 131I tx in as many as 6% and 13% of pts, respectively. When adjusted for pts who reported E&X within 30 days prior to the 131I tx, both the frequency of E&X were not statistically significantly increased. Research Support Biostatistical support for this project has been funded in whole or in part with Federal funds (Grant # UL1RR031975) from the National Center for Research Resources (NCRR), National Institutes of Health (NIH), through the Clinical and Translational Science Awards Program (CTSA), a trademark of DHHS, part of the Roadmap Initiative, “Re-Engineering the Clinical Research Enterprise.